Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 8 Gastrointestinal 8 Other hematologic neoplasm 5 Myeloid 3 Lymphoid 2 Tumor-Agnostic 1 Other solid neoplasm 1 Other neoplasm 1 Dermatologic 1 Classical hematology 1 Breast 1

Conditions

Rare Malignant Neoplasm 1

Interventions

Magnetic Resonance Spectroscopy 3 Biopsy 3 fludarabine 2 Taxes 2 Paclitaxel 2 Endoscopic Mucosal Resection 2 Aminolevulinic Acid 2 Albumin-Bound Paclitaxel 2 130-nm albumin-bound paclitaxel 2 venetoclax 1 trametinib 1 toripalimab 1 thymoglobulin 1 taxane 1 sintilimab 1 potassium oxonate 1 lutetium Lu 177 dotatate 1 gimeracil 1 fludarabine phosphate 1 dabrafenib 1 apatinib 1 Whole-Body Irradiation 1 Watchful Waiting 1 Transurethral Resection of Prostate 1 Tegafur 1 Surgical Procedures, Operative 1 Stem Cell Transplantation 1 Standard of Care 1 Specimen Handling 1 Sirolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Imatinib Mesylate × Other neoplasm × Clear all

NCT06119789 2025-03-26

MATRIX-Rare

Oslo University Hospital

Phase 2 Recruiting

Rare Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon ⚡